In the framework of a nationwide effort, we investigated the clinical value and feasibility of a sensitive ‘snapshot’ screening for the two most common BCL2 mutations associated with acquired venetoclax resistance in a cohort of 67 patients with R/R CLL treated with venetoclax either as monotherapy or in combination with rituximab. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.